{"name":"JOHNSON AND JOHNSON","slug":"johnson-and-johnson","ticker":"","exchange":"","domain":"johnsonandjohnson.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1962-01-01","label":"Grifulvin V first approved","drug":"Grifulvin V","drugSlug":"griseofulvin","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"GRIFULVIN V","genericName":"GRISEOFULVIN, MICROCRYSTALLINE","slug":"griseofulvin-microcrystalline","indication":"Onychomycosis due to dermatophyte","status":"marketed"},{"name":"Grifulvin V","genericName":"GRISEOFULVIN","slug":"griseofulvin","indication":"Onychomycosis due to dermatophyte","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Meclan","genericName":"MECLOCYCLINE","slug":"meclocycline","indication":"Acne vulgaris","status":"marketed"}]}],"pipeline":[{"name":"Meclan","genericName":"MECLOCYCLINE","slug":"meclocycline","phase":"marketed","mechanism":"Small molecule","indications":["Acne vulgaris","Actinomycotic infection","Acute bacterial sinusitis","Acute gonococcal cervicitis","Acute gonococcal endometritis"],"catalyst":""},{"name":"GRIFULVIN V","genericName":"GRISEOFULVIN, MICROCRYSTALLINE","slug":"griseofulvin-microcrystalline","phase":"marketed","mechanism":"Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin","indications":["Onychomycosis due to dermatophyte","Tinea barbae","Tinea capitis","Tinea corporis","Tinea cruris"],"catalyst":""},{"name":"Grifulvin V","genericName":"GRISEOFULVIN","slug":"griseofulvin","phase":"marketed","mechanism":"Solute carrier family 22 member 1","indications":["Onychomycosis due to dermatophyte","Tinea barbae","Tinea capitis","Tinea corporis","Tinea cruris"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":3,"phaseCounts":{"marketed":3},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}